Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : AbbVie Deutschland GmbH & Co. KG
Femme et Homme Max 99 ans
AbbVie Deutschland GmbH & Co. KG
MAJ Il y a 4 ans
A randomized, open-labeled study to evaluate the efficacy and safety of three experimental drugs (ABT-450, ABT-267 and ABT-333) compared with Telaprevir (a licenced product) in people with hepatitis C virus (HCV) who have previously tried and failed other treatments. "Experimental" means that they have not been approved by any regulatory agency for sale to the public
The primary objective of this study is to assess the efficacy (the percentage of subjects achieving 12-week sustained virologic response, SVR12, [HCV RNA < LLOQ 12 weeks post-treatment]) and safety of...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AbbVie Deutschland GmbH & Co. KG
MAJ Il y a 4 ans
A Study Comparing ABT-494 to Placebo in Subjects with Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who have an Inadequate Response to csDMARDs Alone (SELECT-NEXT)
• To compare the efficacy of ABT-494 versus placebo for the treatment of signs and symptoms of subjects with moderately to severely active rheumatoid arthritis (RA) who are on a stable dose of convent...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AbbVie Deutschland GmbH & Co. KG
MAJ Il y a 4 ans
A Randomized, Double-blind, Placebo-controlled, Dose-ranging, Parallel-group Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Evaluate the efficacy and safety of ABT-126 in the treatment of cognitive deficits in schizophrenia (CDS).
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AbbVie Deutschland GmbH & Co. KG
MAJ Il y a 4 ans
A study to evaluate the safety and effect of treatment with experimental antiviral drugs in combination with peginterferon α-2a and ribavirin in people with hepatitis C virus who did not respond to treatment in a previous AbbVie or Abbott combination study
The primary objective of this study is to evaluate the safety and antiviral efficacy, defined as the percentage of subjects with sustained virologic response 12 weeks post-dosing (SVR12; HCV RNA < LLO...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AbbVie Deutschland GmbH & Co. KG
MAJ Il y a 4 ans
A Phase 2, Multicenter, Open-Label Extension (OLE) Study with ABT-122 in Active Psoriatic Arthritis Subjects Who Have Completed a Preceding Study M14-197 Phase 2 Randomized Controlled Trial (RCT) Estudio de extensión en fase II, multicéntrico y abierto (EEA) con ABT-122 en pacientes con artritis psoriásica activa que han completado el estudio previo en fase II, controlado y aleatorizado (ECA), M14-197
Assess the long term efficacy, and safety and tolerability of ABT-122 in psoriatic arthritis (PsA) subjects on background methotrexate (MTX) who have completed Study M14-197 Phase 2 RCT. Evaluar...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
AbbVie Deutschland GmbH & Co. KG
MAJ Il y a 4 ans
A study evaluating venetoclax (ABT-199) in subjects with Chronic Lymphocytic Leukemia (CLL) whose cancer has come back or who had no response to previous cancer treatments including subjects who may be missing part of their chromosome 17 identified as 17p deletion, or TP53 gene mutation; or subjects who have received prior treatment with a B-Cell receptor inhibitor
The primary objective of this study to evaluate the impact of venetoclax monotherapy on the quality of life of subjects with relapsed or refractory chronic lymphocytic leukemia (CLL) including those w...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
AbbVie Deutschland GmbH & Co. KG
MAJ Il y a 4 ans
Long-Term Safety and Efficacy of ABT-126 in Subjects with Schizophrenia: A Double-Blind Extension Study for Subjects Completing Study M10-855
The objective of this study is to obtain long-term safety, efficacy and health outcomes data in patients with schizophrenia.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme Max 99 ans
AbbVie Deutschland GmbH & Co. KG
MAJ Il y a 4 ans
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Elagolix in Subjects with Moderate to Severe Endometriosis- Associated Pain
To evaluate the safety, tolerability and efficacy of elagolix (ABT-620), administered once daily (QD) or twice daily (BID) for 3 months in the management of moderate to severe endometriosis-associated...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AbbVie Deutschland GmbH & Co. KG
MAJ Il y a 4 ans
A study evaluating venetoclax (ABT-199) in subjects with Chronic Lymphocytic Leukemia (CLL) whose cancer has come back or who had no response to previous cancer treatments including subjects who may be missing part of their chromosome 17 identified as 17p deletion, or TP53 gene mutation; or subjects who did not respond to or did not tolerate treatment with B-cell receptor inhibitors
The primary objective of this study to evaluate the efficacy of venetoclax monotherapy in subjects with relapsed or refractory chronic lymphocytic leukemia (CLL) including those with the 17p deletion ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
AbbVie Deutschland GmbH & Co. KG
MAJ Il y a 4 ans
A study to evaluate the long-term safety of adalimumab in subjects with non-infectious intermediate-, posterior-, or pan-uveitis who participated in Study M10-877 or Study M10-880
The primary objective of this study is to evaluate the long-term safety of adalimumab 40 mg given every other week (eow) subcutaneously (SC) in subjects with non-infectious intermediate-, posterior-, ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Précédent
1
2
3
4
5
6
7
8
9
10
Suivant